Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• DLX2 marks an immunosuppressive dendritic-cell program that reshapes cytotoxic immunity and marks a tolerogenic microenvironment in lung adenocarcinoma.

  PMID 41761000 · PMC13043845 · Discover oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  Neuroactive ligand–receptor signaling is among the most significantly upregulated pathways in LUAD relative to normal lung tissue.

  tcga-luad tcga luad dendritic-cell bulk survival pan-cancer

• Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study.

  PMID 41660271 · PMC12876322 · iScience · 2026 · 8 claims · 8 setups

  Full-text index only

  A 9-gene Immune-Chemotherapy Prediction Score (ICPscore), derived from ORIENT-11 via WGCNA and LASSO Cox regression, predicts survival benefit from ICI plus chemotherapy in advanced NSCLC

  orient-11 hub nsclc oak bulk pd-l1 wgcna

• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

  PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.

  trp53-null complete t12 cell-deficient imaging survival tumor